Columbia University-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Columbia University - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014368
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:58
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Columbia University (CU) is an educational service provider that offers educational and research programs. The university provides educational services and courses through its schools, departments, faculties, centers and institutes. It provides undergraduate and graduate courses in various disciplines including architecture, planning and preservation, arts, sciences, social sciences, dental medicine, engineering, law, social work, nursing and public health, among others. CU conducts research through its research institutes and centers in the areas of natural and bio-medical sciences, social sciences and humanities. The university also conducts various research and clinical programs. CU is headquartered in New York, the US.

Columbia University – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Columbia University, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Columbia University, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Columbia University, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Columbia University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Columbia University, Medical Devices Deals, 2011 to YTD 2017 11
Columbia University, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Columbia University, Pharmaceuticals & Healthcare, Deal Details 14
Partnerships 14
Verge Genomics Enters into Agreement with Columbia University, Massachusetts General Hospital, University of Southern California, and University of Michigan 14
Atossa Genetics Enters into Agreement with Columbia University Medical Center 15
Biogen Idec Enters into Research Agreement with Columbia University Medical Center 16
Cancer Genetics Enters into Co-Development Agreement with Columbia University Medical Center 17
CSPC ZhongQi Pharma to Enter into Co-Development Agreement with Columbia University 18
Genia Technologies Enters Into Agreement With Columbia University And Harvard Medical To Develop NanoTag DNA Sequencing Technology 19
Sanofi-aventis Enters Into Research Collaboration With Columbia University 20
Licensing Agreements 21
Lin Bioscience Enters into Licensing Agreement with Columbia University and Memorial Sloan Kettering Cancer Center 21
Lin Bioscience Enters into Licensing Agreement with Columbia Technology Ventures 22
Fortress Biotech Enters into Licensing Agreement with Columbia University 23
Heat Biologics Enters into Licensing Agreement with Columbia University 24
vTv Therapeutics Enters into Licensing Agreement with Columbia University 25
ALSP Enters Into Licensing Agreement with Columbia University 26
iCura Vision Enters into Licensing Agreement with Columbia Technology Ventures 27
Sapience Therapeutics Enters into Licensing Agreement with Columbia University 28
Vor BioPharma Enters into Licensing Agreement with Columbia University 29
Apeiron Biologics Enters into Licensing Agreement with Columbia University 30
Kyras Therapeutics Enters into Agreement with Columbia University 31
Roche Diagnostics Enters Into Licensing Agreement With Arizona Technology And Columbia University 32
China Institute of Strategy and Management Lanmeng Investment Enters Into Licensing Agreement With Columbia University 33
Columbia University Enters Into Licensing Agreement With Alkeus Pharma 34
Columbia University – Key Competitors 35
Columbia University – Key Employees 36
Columbia University – Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Recent Developments 39
Government and Public Interest 39
Nov 16, 2017: Irving Family’s $700 Million Bequest to Columbia University and NewYork-Presbyterian Sets Stage for Dramatic Advances in Cancer Research and Care 39
Nov 08, 2017: Mechanical heart valve often the safest choice 41
Oct 16, 2017: Cancer Researchers at Wake Forest Baptist Receive $9 Million Grant to Study Aggressive Brain Cancer 43
Oct 02, 2017: DSI Professor Conducts Research to Combat Pancreatic Cancer 44
Sep 27, 2017: NIH announces centers for myalgic encephalomyelitis/chronic fatigue syndrome research 45
Sep 27, 2017: NIH Awards $9.6 Million Grant to Columbia for a Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Collaborative Research Center 47
Sep 08, 2016: New Vaccination Strategies Successfully Coach Immune System to Make Powerful HIV-Neutralizing Antibodies 49
Jul 18, 2016: Toxic Alzheimer’s Protein Spreads Through Brain Via Extracellular Space 51
Jul 14, 2016: Columbia University Awarded $58.4 Million to Accelerate Development of New Therapies 52
Apr 21, 2016: Columbia Engineering-led Team Advances Single Molecule Electronic DNA Sequencing—A Future Platform for Precision Medicine 54
Feb 17, 2016: Cancer Study is ‘Paradigm Shift’ in Cause of Tumor Formation 56
Jan 21, 2016: Columbia Neuroscientists Develop New Tools to Safely Trace Brain Circuits 57
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58

List of Tables
Columbia University, Pharmaceuticals & Healthcare, Key Facts 2
Columbia University, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Columbia University, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Columbia University, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Columbia University, Deals By Therapy Area, 2011 to YTD 2017 9
Columbia University, Medical Devices Deals, 2011 to YTD 2017 11
Columbia University, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Verge Genomics Enters into Agreement with Columbia University, Massachusetts General Hospital, University of Southern California, and University of Michigan 14
Atossa Genetics Enters into Agreement with Columbia University Medical Center 15
Biogen Idec Enters into Research Agreement with Columbia University Medical Center 16
Cancer Genetics Enters into Co-Development Agreement with Columbia University Medical Center 17
CSPC ZhongQi Pharma to Enter into Co-Development Agreement with Columbia University 18
Genia Technologies Enters Into Agreement With Columbia University And Harvard Medical To Develop NanoTag DNA Sequencing Technology 19
Sanofi-aventis Enters Into Research Collaboration With Columbia University 20
Lin Bioscience Enters into Licensing Agreement with Columbia University and Memorial Sloan Kettering Cancer Center 21
Lin Bioscience Enters into Licensing Agreement with Columbia Technology Ventures 22
Fortress Biotech Enters into Licensing Agreement with Columbia University 23
Heat Biologics Enters into Licensing Agreement with Columbia University 24
vTv Therapeutics Enters into Licensing Agreement with Columbia University 25
ALSP Enters Into Licensing Agreement with Columbia University 26
iCura Vision Enters into Licensing Agreement with Columbia Technology Ventures 27
Sapience Therapeutics Enters into Licensing Agreement with Columbia University 28
Vor BioPharma Enters into Licensing Agreement with Columbia University 29
Apeiron Biologics Enters into Licensing Agreement with Columbia University 30
Kyras Therapeutics Enters into Agreement with Columbia University 31
Roche Diagnostics Enters Into Licensing Agreement With Arizona Technology And Columbia University 32
China Institute of Strategy and Management Lanmeng Investment Enters Into Licensing Agreement With Columbia University 33
Columbia University Enters Into Licensing Agreement With Alkeus Pharma 34
Columbia University, Key Competitors 35
Columbia University, Key Employees 36
Columbia University, Subsidiaries 37

★海外企業調査レポート[Columbia University-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Pure Technologies Ltd:企業の戦略的SWOT分析
    Pure Technologies Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Fidelity National Information Services Inc:企業の戦略・SWOT・財務情報
    Fidelity National Information Services Inc - Strategy, SWOT and Corporate Finance Report Summary Fidelity National Information Services Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • ON Semiconductor Corporation:企業の戦略・SWOT・財務情報
    ON Semiconductor Corporation - Strategy, SWOT and Corporate Finance Report Summary ON Semiconductor Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Renco Group SpA:企業の戦略的SWOT分析
    Renco Group SpA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Sanderson Farms Inc:企業の戦略・SWOT・財務分析
    Sanderson Farms Inc - Strategy, SWOT and Corporate Finance Report Summary Sanderson Farms Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Aptech Ltd (APTECHT):企業の財務・戦略的SWOT分析
    Aptech Ltd (APTECHT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • ALTANA AG:戦略・SWOT・企業財務分析
    ALTANA AG - Strategy, SWOT and Corporate Finance Report Summary ALTANA AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Parker Drilling Co (PKD):企業の財務・戦略的SWOT分析
    Parker Drilling Co (PKD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • B. Braun Medical Inc-医療機器分野:企業M&A・提携分析
    Summary B. Braun Medical Inc (B. Braun), a subsidiary of B. Braun Melsungen AG is a medical device company that provides infusion therapy and pain management technology, products and services. The company’s product portfolio includes TPN compounding bags, parenteral nutrition additives, closed syste …
  • Companhia Energetica de Sao Paulo:発電所・企業SWOT分析
    Companhia Energetica de Sao Paulo - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on …
  • Sky plc:企業の戦略・SWOT・財務分析
    Sky plc - Strategy, SWOT and Corporate Finance Report Summary Sky plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Capri Holdings Ltd:企業の戦略・SWOT・財務分析
    Capri Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Capri Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Midas Group Ltd:企業の戦略・SWOT・財務分析
    Midas Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Midas Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • GBST Holdings Limited (GBT):企業の財務・戦略的SWOT分析
    GBST Holdings Limited (GBT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • KCB Group Plc.:企業の戦略・SWOT・財務情報
    KCB Group Plc. - Strategy, SWOT and Corporate Finance Report Summary KCB Group Plc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • NII Holdings Inc (NIHD):企業の財務・戦略的SWOT分析
    Summary NII Holdings Inc (NII Holdings) is a mobile communication service provider that offers communication products and services. The company offers solutions such as 3G mobile broadband services, content downloads and messaging. It also provides digital cellular voice services, data services, and …
  • Novadaq Technologies Inc:医療機器:M&Aディール及び事業提携情報
    Summary Novadaq Technologies Inc (Novadaq) is a medical imaging company. It develops, manufactures and markets real-time fluorescence imaging technology products. The company’s SPY Imaging Technology products include SPY Elite open surgical imaging system, PinPoint endoscopic fluorescence imaging sy …
  • Antibe Therapeutics Inc (ATE):製薬・医療:M&Aディール及び事業提携情報
    Summary Antibe Therapeutics Inc (Antibe) is a biotech company that designs and develops drug candidates for chronic pain and inflammation; and regenerative medicine. The company discovers and commercializes novel drugs, biologics and medical devices. It offers lead compound ATB-346, a naproxen deriv …
  • Huesker Synthetic GmbH:企業の戦略・SWOT・財務情報
    Huesker Synthetic GmbH - Strategy, SWOT and Corporate Finance Report Summary Huesker Synthetic GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Verbundnetz Gas Aktiengesellschaft:石油・ガス:M&Aディール及び事業提携情報
    Summary Verbundnetz Gas AG (VNG), a subsidiary of EnBW Energie Baden-Wurttemberg AG, is a natural gas company that explores, produces, stores, trades and transports natural gas. The company has natural gas licenses on the Norwegian continental shelf and the Danish North Sea. VNG also offers gas stor …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆